Recently Featured

Vaccine Void Means Current Ebola Outbreak Declared International Emergency

June 13, 2026
The World Health Organization (WHO) has officially classified the ongoing Ebola outbreak as an international emergency, citing an alarming lack of effective therapeutic options and concerning epidemiological trends. This designation underscores the severity of the situation, as the outbreak continues to spread without adequate vaccines or treatments to contain it. The absence of a robust…

Merck ADC, licensed from China, hits mark in first big global trial

June 13, 2026
Merck’s recent endometrial cancer trial marks a significant milestone as the first of 17 late-stage studies for a therapy that plays a crucial role in the company’s strategy to achieve $70 billion in annual sales by the end of the decade. This trial, utilizing an antibody-drug conjugate (ADC) licensed from a Chinese biotech firm, showcases…

Høeg Fired in Latest FDA Shakeup; 20 People Die After Taking Amgen Drug

June 13, 2026
The recent dismissal of FDA official Høeg marks a significant leadership change within the agency, particularly affecting two key drug review offices. This shakeup comes in the wake of troubling reports that 20 individuals have died after using a drug developed by Amgen, raising serious questions about the agency’s oversight and regulatory processes. Such incidents…

Merck’s ADC sac-TMT Achieves First Global Phase 3 Success Ahead of Schedule

June 12, 2026
Merck’s experimental antibody-drug conjugate (ADC) sac-TMT has successfully completed its first global Phase 3 study ahead of schedule, marking a significant milestone for the company as it navigates the impending patent expiration of its leading products. This achievement not only reinforces Merck’s commitment to advancing innovative therapies but also highlights the strategic collaboration with China-based…

Ongoing Cases